Sangamo reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Sangamo BioSciences, Inc. at market outperform on news of the company's second-quarter earnings that were roughly in line with the analyst's estimates. As a result, JMP increased its full-year 2006 revenue estimates to $8.2 million from $7.7 million and its full-year 2006 net loss projections to $0.43 per share from $0.39. Shares of the Richmond, Calif.-based pharmaceutical company were down 23 cents, or 4.64%, at $4.73 on volume of 108,728 shares versus the three-month running average of 363,222 shares. (Nasdaq: SGMO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.